EE213 Cost-Effectiveness Analysis of Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, and Standard of Care for Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.462
https://www.valueinhealthjournal.com/article/S1098-3015(22)00663-5/fulltext
Title :
EE213 Cost-Effectiveness Analysis of Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, and Standard of Care for Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00663-5&doi=10.1016/j.jval.2022.04.462
First page :
Section Title :
Open access? :
No
Section Order :
10409